[go: up one dir, main page]

NO20042565L - Orale farmasoytiske produkter inneholdende 17 beta-ostradiol-3-lavere alkanoat, fremgangsmater for administrering av disse og fremgangsmater for fremstilling derav - Google Patents

Orale farmasoytiske produkter inneholdende 17 beta-ostradiol-3-lavere alkanoat, fremgangsmater for administrering av disse og fremgangsmater for fremstilling derav

Info

Publication number
NO20042565L
NO20042565L NO20042565A NO20042565A NO20042565L NO 20042565 L NO20042565 L NO 20042565L NO 20042565 A NO20042565 A NO 20042565A NO 20042565 A NO20042565 A NO 20042565A NO 20042565 L NO20042565 L NO 20042565L
Authority
NO
Norway
Prior art keywords
methods
ostradiol
beta
administration
preparation
Prior art date
Application number
NO20042565A
Other languages
English (en)
Norwegian (no)
Inventor
Oluwole T Aloba
Tina M De Vries
Original Assignee
Galen Chemicals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Galen Chemicals Ltd filed Critical Galen Chemicals Ltd
Publication of NO20042565L publication Critical patent/NO20042565L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/34—Gestagens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Reproductive Health (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Gynecology & Obstetrics (AREA)
  • Dermatology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Cardiology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NO20042565A 2001-12-21 2004-06-18 Orale farmasoytiske produkter inneholdende 17 beta-ostradiol-3-lavere alkanoat, fremgangsmater for administrering av disse og fremgangsmater for fremstilling derav NO20042565L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/023,748 US6962908B2 (en) 2001-12-21 2001-12-21 Oral pharmaceutical products containing 17 β-estradiol-3-lower alkanoate, method of administering the same and process of preparation
PCT/US2002/040728 WO2003055495A1 (fr) 2001-12-21 2002-12-20 Produits pharmaceutiques oraux renfermant 17$g(b)-estradiol-3- alcanoate inferieur, procede d'administration et de preparation associes

Publications (1)

Publication Number Publication Date
NO20042565L true NO20042565L (no) 2004-06-18

Family

ID=21816969

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20042565A NO20042565L (no) 2001-12-21 2004-06-18 Orale farmasoytiske produkter inneholdende 17 beta-ostradiol-3-lavere alkanoat, fremgangsmater for administrering av disse og fremgangsmater for fremstilling derav

Country Status (11)

Country Link
US (3) US6962908B2 (fr)
EP (1) EP1461043A1 (fr)
JP (1) JP2005517673A (fr)
CN (1) CN1273141C (fr)
AU (1) AU2002359758A1 (fr)
CA (1) CA2470703C (fr)
IL (2) IL160797A0 (fr)
MX (1) MXPA04006057A (fr)
NO (1) NO20042565L (fr)
NZ (1) NZ532491A (fr)
WO (1) WO2003055495A1 (fr)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020132801A1 (en) * 2001-01-11 2002-09-19 Schering Aktiengesellschaft Drospirenone for hormone replacement therapy
FR2857591B1 (fr) * 2003-07-17 2007-11-02 Ethypharm Sa Particules comprenant un principe actif sous forme de co-precipite
JP2007506796A (ja) * 2003-09-29 2007-03-22 ノボ・ノルディスク・フェムケア・アーゲー Ｈｒｔ製剤
AU2004275470B2 (en) * 2003-09-29 2010-12-02 Novo Nordisk Health Care Ag Improved stability of progestogen formulations
EP1680144B1 (fr) * 2003-10-08 2011-10-05 Mallinckrodt LLC Solution de methylphenidate et procedes associes d'administration et de production
GT200500315A (es) * 2004-11-02 2006-06-06 Formas de dosificacion oral solidas que contienen una dosis baja de estradiol
US8022053B2 (en) * 2004-11-02 2011-09-20 Bayer Schering Pharma Aktiengesellschaft Oral solid dosage forms containing a low dose of estradiol
WO2006116514A2 (fr) 2005-04-28 2006-11-02 Wyeth Tanaproget micronise, compositions et procede pour les preparer
DE602006013114D1 (de) * 2005-04-28 2010-05-06 Wyeth Corp Mikronisiertes tanaproget und zusammensetzungen damit
JP5649305B2 (ja) * 2006-12-20 2015-01-07 テバ ウィメンズ ヘルス インコーポレイテッド プロゲスチンを含む口腔内崩壊性固体剤形ならびにその製造方法および使用方法
US20100061976A1 (en) * 2008-07-24 2010-03-11 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Method for treating or preventing osteoporosis by reducing follicle stimulating hormone to cyclic physiological levels in a mammalian subject
US20100022497A1 (en) * 2008-07-24 2010-01-28 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Method for treating or preventing a cardiovascular disease or condition utilizing estrogen receptor modulators based on APOE allelic profile of a mammalian subject
US20100022991A1 (en) * 2008-07-24 2010-01-28 Searete Llc, A Limited Liability Corporation Of The State Of Delaware System and device for maintaining physiological levels of steroid hormone in a subject
US20100022494A1 (en) * 2008-07-24 2010-01-28 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Method, device, and kit for maintaining physiological levels of steroid hormone in a subject
US20110190201A1 (en) * 2008-07-24 2011-08-04 Searete Llc Method, device, and kit for maintaining physiological levels of steroid hormone in a subject
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
RS62297B1 (sr) 2011-11-23 2021-09-30 Therapeuticsmd Inc Prirodne kombinovane hormonske supstitucione formulacije i terapije
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
JP2017516768A (ja) 2014-05-22 2017-06-22 セラピューティックスエムディー インコーポレーテッドＴｈｅｒａｐｅｕｔｉｃｓｍｄ， Ｉｎｃ． 天然の併用ホルモン補充療法剤及び療法
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
US10286077B2 (en) 2016-04-01 2019-05-14 Therapeuticsmd, Inc. Steroid hormone compositions in medium chain oils
US9931349B2 (en) 2016-04-01 2018-04-03 Therapeuticsmd, Inc. Steroid hormone pharmaceutical composition
US11633405B2 (en) 2020-02-07 2023-04-25 Therapeuticsmd, Inc. Steroid hormone pharmaceutical formulations
CN114573654B (zh) * 2020-12-01 2025-09-12 北京奇明达企业管理有限公司 17-O-乙酰-17-β雌二醇的自组装的三聚体、其制备、活性和应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE699310C (de) * 1936-11-20 1940-11-27 Chemische Ind Ges Verfahren zur Herstellung von in 3-Stellung veresterten Verbindungen vom Typus des Oestradiols
US3568828A (en) 1967-03-01 1971-03-09 Squibb & Sons Inc Modified sequential oral contraceptive
US3478070A (en) * 1967-12-26 1969-11-11 American Home Prod Process for selectively acylating the 3-ol group in polyhydroxy 13-alkyl gona-(and 8 - isogona) - 1,3,5 - (10) - trienes and delta - 7 -,delta - 8(9),delta - 9(11) -,and delta - 8(9),14(15) - dehydro derivatives thereof
US4544554A (en) 1983-09-26 1985-10-01 Ortho Pharmaceutical Corporation Triphasic oral contraceptive
IE67345B1 (en) 1991-03-12 1996-03-20 Akzo Nv Low dose dry pharmaceutical preparations
US5928668A (en) 1993-12-21 1999-07-27 Applied Analytical Industries, Inc. Method for dry blend compression of medicaments
US5976570A (en) 1993-12-21 1999-11-02 Applied Analytical Industries, Inc. Method for preparing low dose pharmaceutical products
DE4344462C2 (de) * 1993-12-22 1996-02-01 Schering Ag Zusammensetzung für die Empfängnisverhütung
IL116433A (en) 1994-12-19 2002-02-10 Galen Chemicals Ltd INTRAVAGINAL DRUG DELIVERY DEVICES FOR THE ADMINISTRATION OF 17β-OESTRADIOL PRECURSORS
US6117446A (en) * 1999-01-26 2000-09-12 Place; Virgil A. Drug dosage unit for buccal administration of steroidal active agents

Also Published As

Publication number Publication date
AU2002359758A1 (en) 2003-07-15
IL160797A (en) 2013-11-28
IL160797A0 (en) 2004-08-31
US20030118638A1 (en) 2003-06-26
CA2470703A1 (fr) 2003-07-10
EP1461043A1 (fr) 2004-09-29
MXPA04006057A (es) 2005-04-19
CN1564689A (zh) 2005-01-12
CN1273141C (zh) 2006-09-06
US7572779B2 (en) 2009-08-11
WO2003055495A1 (fr) 2003-07-10
CA2470703C (fr) 2011-03-15
US20050234028A1 (en) 2005-10-20
NZ532491A (en) 2005-05-27
US6962908B2 (en) 2005-11-08
JP2005517673A (ja) 2005-06-16
US7799771B2 (en) 2010-09-21
US20040209856A1 (en) 2004-10-21

Similar Documents

Publication Publication Date Title
NO20042565L (no) Orale farmasoytiske produkter inneholdende 17 beta-ostradiol-3-lavere alkanoat, fremgangsmater for administrering av disse og fremgangsmater for fremstilling derav
LTC1345910I2 (lt) Chinazolidino dariniai, minėtus junginius turintys vaistai, jų panaudojimas ir jų gavimo būdas
AU2002357012A1 (en) Oral pharmaceutical formulations comprising paclitaxel, derivatives and methods of administration thereof
NO20022998L (no) Farmasöytiske preparater som tilveiebringer foröket konsentrasjon av medikament
NO20016277D0 (no) Systemer og fremgangsmåter for aerolisering av farmasöytiske formuleringer
NO20034079L (no) Fremgangsmåte for fremstilling av interpolymerer og produkter laget derav
NO996433L (no) Nye formuleringer av legemidler, fremgangsmåter for fremstilling derav og fremgangsmåter for anvendelse derav
ATE317260T1 (de) Pharmazeutische formulierungen mit platinderivaten
NO20010277L (no) Benzocykloheptener, fremgangsmÕte for fremstilling derav, farmasøytiske preparater inneholdende disse, og deres anvendelse for fremstilling av medikamenter
NO20040268L (no) Nye 2H-pyridazin-3-derivater, farmasoytiske preparater inneholdende slike og fremgangsmate for fremstilling av den aktive ingrediensen
NO984878D0 (no) Fremstilling og anvendelse som medikamenter av 3-alkoksypyridin-2-karboksylsyreamidestere
NO20026212D0 (no) Forbindelse for medikamentavleveringssystem og fremgangsmåte for fremstilling av forbindelsen
NO20015659L (no) Purinderivater, fremstillingsmetode og farmasöytiske preparater inneholdende disse
NO20001717D0 (no) Serotonin-inneholdende formulering for oral administrering og anvendelse av samme
EE200300135A (et) Trüptamiini derivaadid ja analoogsed ühendid ningneid sisaldavad farmatseutilised preparaadid
DK1275647T3 (da) Octahydro-1H-pyrido[1,2-a]pyrazinderivater, fremgangsmåde til fremstilling heraf og farmaceutiske sammensætninger indeholdende disse
NO20043007L (no) Farmasoytisk suspensjon for oral administrering
NO20023249D0 (no) Nye substituerte pyrazolo(4,3-e)ediazepiner, farmasöytiske preparater inneholdende disse, anvendelse som medisinske produkterog fremgangsmåter for fremstilling derav
DK1215213T3 (da) Bicylliske aminopyrazinonderivater, fremstilling deraf og farmaceutiske sammensætninger, som indeholder disse
NO20013141D0 (no) Arylalkanoylderivater, fremgangsmåte for fremstilling derav, deres anvendelse og farmasöytiske produkter inneholdende disse
NO20020777D0 (no) Farmasöytiske preparater inneholdende derivater og fremgangsmåte for fremstilling derav
PL369632A1 (en) Novel 5-thio-ss-d-xylopyranoside derivatives, preparation method thereof, pharmaceutical compositions containing same and the therapeutic use thereof
NO20042022L (no) Fast legemiddelformulering som inneholder pipiperazinurea-derivat og fremgangsmate for fremstilling av formuleringen
EE200300436A (et) Imidasolidiini derivaadid, nende valmistamine ja kasutamine põletikuvastaste toimeainetena ning neid sisaldav ravimpreparaat
DE60214533D1 (de) Pyridoindolonderivate und antikrebsmittel enthaltende pharmazeutische mischungen

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application